Related Experiment Videos

Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits

Insights

Liposomal amphotericin B significantly reduces ocular toxicity compared to commercial amphotericin B. This liposomal formulation shows improved safety for intravitreal injection in rabbits.

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Drug Delivery Systems

Background:

  • Amphotericin B is a critical antifungal agent.
  • Ocular toxicity is a concern with intravitreal amphotericin B injections.
  • Liposomal formulations aim to improve drug safety and efficacy.

Purpose of the Study:

  • To compare the ocular toxicity of liposomal amphotericin B (L-AMB) versus commercial amphotericin B (C-AMB).
  • To evaluate the safety of intravitreal injections of these formulations in a rabbit model.

Main Methods:

  • Intravitreal injections of L-AMB and C-AMB were administered to healthy pigmented rabbits.
  • Ophthalmoscopic and histopathologic examinations were conducted over 5 weeks.
  • Vitreous humor concentrations of amphotericin B were measured.

Main Results:

  • Commercial amphotericin B caused retinal damage and vitreal bands at doses as low as 5 micrograms.
  • Liposomal amphotericin B did not cause these lesions at doses up to 20 micrograms.
  • Histopathology confirmed reduced retinal atrophy/necrosis with L-AMB (P = 0.02).

Conclusions:

  • Liposome association markedly reduces the ocular toxicity of amphotericin B.
  • Liposomal amphotericin B demonstrates a significantly improved ocular safety profile.
  • This suggests L-AMB as a potentially safer alternative for intravitreal antifungal therapy.

Related Concept Videos